Ixazomib and lenalidomide maintenance therapy in multiple myeloma

Ann Hematol. 2021 Mar;100(3):851-853. doi: 10.1007/s00277-020-04340-8. Epub 2020 Nov 8.

Authors

Ricardo D Parrondo¹, Victoria Alegria¹, Vivek Roy¹, Taimur Sher¹, Asher A Chanan-Khan¹, Sikander Ailawadhi²

Affiliations

¹ Deparment of Hematology-Oncology, Mayo Clinic Florida, Mangurian Building, 3rd Floor, 4500 San Pablo Road S, Jacksonville, FL, 32224, USA.
² Deparment of Hematology-Oncology, Mayo Clinic Florida, Mangurian Building, 3rd Floor, 4500 San Pablo Road S, Jacksonville, FL, 32224, USA. [email protected].

PMID: 33161454
DOI: 10.1007/s00277-020-04340-8

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Boron Compounds / administration & dosage
Boron Compounds / adverse effects
Female
Glycine / administration & dosage
Glycine / adverse effects
Glycine / analogs & derivatives
Humans
Lenalidomide / administration & dosage
Lenalidomide / adverse effects
Maintenance Chemotherapy*
Male
Middle Aged
Multiple Myeloma / drug therapy*

Substances

Boron Compounds
ixazomib
Lenalidomide
Glycine